Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors

Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors
复制标题

DOI:
10.1017/s0007114511002431
复制
发表时间:
2011-11-01
影响因子:
3.6
通讯作者:
Stroes, Erik S. G.
Stroes, Erik S. G.
中科院分区:
医学3区
文献类型:
--
作者:
Broekhuizen, Lysette N.;van Wijk, Diederik F.;Stroes, Erik S. G.

文献摘要

被引文献

相似文献

炎症是代谢综合征的标志,其也有助于促动脉粥样硬化状态。NF-κ B B活化是调节炎症反应的关键步骤,至少在体外可被多酚(PF)提取物抑制。在本研究中,我们着手研究富含PF的提取物是否可以减轻具有聚集代谢危险因素的受试者体内的慢性炎症状态和/或急性免疫应答。采用随机、双盲、交叉设计,对34名具有两种或两种以上代谢危险因素的受试者给予市售的富含PF的提取物(每日500 mg)或安慰剂4周。在最终研究访视期间,对随机分组的受试者(富含PF的提取物(n 12)和安慰剂(n 12))进行急性炎症激发(脂多糖(LPS)1 ng/kg体重)。富含PF的提取物适度降低了炎症趋化因子单核细胞趋化蛋白1(MCP-1)和巨噬细胞移动抑制因子(MIF)(MCP-1 26.5%(PF,中位数116(四分位数范围97-136)pg/ml v.安慰剂,中位数124(四分位数范围105-153)pg/ml; P
Inflammation is a hallmark of the metabolic syndrome, which also contributes to a pro-atherogenic state. NF-kappa B activation, a critical step in regulating inflammatory reactions, can be inhibited by polyphenol (PF) extracts, at least in vitro. In the present study, we set out to study whether a PF-rich extract could attenuate the chronic inflammatory state and/or an acute immune response in vivo in subjects with clustered metabolic risk factors. A commercially available, PF-rich extract (500mg daily) or placebo was administered for 4 weeks to thirty-four subjects with two or more metabolic risk factors using a randomised, double-blind, cross-over design. During the final study visit, an acute inflammatory challenge (lipopolysaccharide (LPS) 1 ng/kg body weight) was administered to a random subgroup of subjects (PF-rich extract (n 12) and placebo (n 12)). The PF-rich extract modestly reduced the inflammatory chemokines monocyte chemoattractant protein 1 (MCP-1) and macrophage migration inhibitory factor (MIF) (MCP-1 26.5% (PF, median 116 (interquartile range 97-136) pg/ml v. placebo, median 124 (interquartile range 105-153) pg/ml; P